Drug Trial Radar · NCT05142514
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
629
Actual
Start
Nov 11, 2021
Primary completion
May 6, 2022
Study completion May 6, 2022
Sponsor
- Lead sponsor
- Hipra Scientific, S.L.UIndustry
- Sponsor type
- Industry
- Collaborators
- Laboratorios Hipra, S.A.; National Institute of Hygiene and Epidemiology, Vietnam
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
Conditions
- SARS-CoV-2 Infection
Interventions
COVID-19 Vaccine HIPRABiological
Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart
Cominarty (Pfizer-BioNtech)Biological
Subjects will receive 2 injections of Cominarty administered 21 days apart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 7 days
- Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 28 days
- Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 7 days
- Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 30 weeks
- Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 30 weeks
- Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteersTime frame: 30 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Hygiene and Epidemiology
Hanoi, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.